Search

Your search keyword '"Cespiati A"' showing total 274 results

Search Constraints

Start Over You searched for: Author "Cespiati A" Remove constraint Author: "Cespiati A"
274 results on '"Cespiati A"'

Search Results

1. The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic

2. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy

4. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis

5. Portal hypertension-like pattern in coronavirus disease 2019 acute respiratory distress syndrome

6. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors

7. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy

8. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives

9. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

12. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy

13. Artificial intelligence as a ploy to delve into the intricate relationship between genetics and mitochondria in MASLD patients

14. FRI-294 Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study

15. FRI-248-YI The impact of baseline sarcopenia, over time, on liver and cardiovascular damage in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a prospective study

16. THU-161 Hepatic sarcoidosis diagnosis and management: an italian multicenter study

17. FRI-207-YI Sarcopenia in metabolic-dysfunction associated steatotic liver disease (MASLD): unraveling its role in cardiovascular damage

18. FRI-226 The impact of light to moderate alcohol consumption on liver and cardiovascular damage in metabolic-dysfunction associated steatotic liver disease

19. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

20. Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population

21. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis

22. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy

23. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

24. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives.

25. The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes.

27. Correction to: Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register (Internal and Emergency Medicine, (2023), 18, 4, (1049-1063), 10.1007/s11739-023-03254-3)

28. Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register

29. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

30. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review.

31. Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population

32. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors

33. Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies

34. Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown

35. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

36. A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced NAFLD: first report

37. Metabolic associated fatty liver disease: different impact of the three defining criteria on the hepatic and cardiovascular complications

38. Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease

40. SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

41. Glomerular hyperfiltration: a new marker of fibrosis severity in non-cirrhotic non-alcoholic fatty liver disease

42. Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry

43. External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019

44. Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment

45. Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment

46. Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity

49. Survey on hepatic sarcoidosis in Italy

50. SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: A five-year follow-up study

Catalog

Books, media, physical & digital resources